ReviewThe British journal of radiology2020
The evolution of interventional oncology in the 21st century.
Review in The British journal of radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Balloon-Occluded Hepatic Radioembolization with Yttrium-90 (b-TARE) in Selected Patients with Unresectable Heterogeneous Hepatocellular Carcinoma (HCC): A Safe and Effective Approach to Improve the Dose Rate.Diagnostics (Basel, Switzerland) · 2025Article
- Progress of Immune-Inducible Biomaterials for Post-Ablation Cancers.Advanced healthcare materials · 2025Review
- Analysis of tumor treatment under interventional ultrasound through structural and temporal dynamics: a bibliometric visualization.Quantitative imaging in medicine and surgery · 2024Article
- Liquid nitrogen-based cryoablation: complication rates for lung, bone, and soft tissue tumors cryoablation.The British journal of radiology · 2024Article
- ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023.JCO global oncology · 2023Article
- Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends.International journal of molecular sciences · 2023Review
- Safety and Feasibility of Analgosedation for Electrochemotherapy of Liver Lesions.Life (Basel, Switzerland) · 2023Article
- Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments.Cancers · 2023Review
- Immune Effects of Cryoablation in Woodchuck Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023Article
- Challenges associated with the integration of immuno-oncology agents in clinical practice.BMC medical education · 2022Article
- A national dose analysis of guided tumor destruction: influence of sex, age, localization and destruction technique used.Quantitative imaging in medicine and surgery · 2022Article
- Modulating the tumor immune microenvironment with locoregional image-guided interventions.Frontiers in immunology · 2022Review
- 125 years ofThe British journal of radiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interventional oncology (IO) has proven to be highly efficient in the local therapy of numerous malignant tumors in addition to surgery, chemotherapy, and radiotherapy. Due to the advent of immune-oncology with the possibility of tumor control at the molecular and cellular levels, a system change is currently emerging. This will significantly rule oncology in the coming decades. Therefore, one cannot think about IO in the 21st century without considering immunology. For IO, this means paying much more attention to the immunomodulatory effects of the interventional techniques, which have so far been neglected, and to explore the synergistic possibilities with immuno-oncology. It can be expected that the combined use of IO and immuno-oncology will help to overcome the limitations of the latter, such as limited local effects and a high rate of side-effects. To do this, however, sectoral boundaries must be removed and interdisciplinary research efforts must be strengthened. In case of success, IO will face an exciting future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.